Pivotal Acquisition Corp. Files for $200 Million SPAC
by Kristi Marvin on 2018-12-27 at 1:06pm

Last night, while everyone was still recovering from the Christmas holiday, another new SPAC was filed making the forthcoming 2019 IPO count SIX.  This latest SPAC is Pivotal Acquisition Corp., a $200 million IPO being led by none other than Jonathan Ledecky, one of the more prolific SPAC issuers, circa 2005 to 2009, setting the template for serial SPAC issuers such as the Gores and Fintech teams.

For those unfamiliar with SPAC history, Jonathan Ledecky led Endeavor Acquisition, a 2005 SPAC that subsequently combined with American Apparel for approximately $395 million and at that time, it was pretty big news.  Whatever you may think of American Apparel now, it was a hot company in the mid-2000’s and having a SPAC (!) acquire the company made headlines.  In fact, Endeavor and Services Acquisition (which bought Jamba Juice) were part of the wave of 2005 SPACs that made investors sit up and take notice and created huge demand for the SPAC product.

Mr. Ledecky went on to lead two more SPACs in quick succession – Victory Acquisition Corp. ($330 million) and Triplecrown Acquisition Corp. ($552 million).  However, timing is everything and the financial crisis brought the SPAC market to a grinding halt (as well as pretty much everything else).  Victory never got to make an acquisition and as with so many of the 2007 SPACs, had to liquidate.  Triplecrown combined in 2009 with Cullen Agricultural Technologies, a dairy and agricultural company – also not great timing.  If you were around in that era, it was a real bloodbath in SPACland.

But here we are in 2019, and Mr. Ledecky is back. So let’s take a look at the terms of his new deal:

Pivotal terms

Looking at the terms, the structure feels appropriate.  Could they have been more aggressive and gone with a 1/2 warrant or maybe 24 months?  Yeah.  But the SPAC road has been bumpy as of late and we’ve had a number of deals execute poorly (IAM, STLR, DOTA), so investors aren’t going to be very agreeable.  With that thought in mind, it’s a little dangerous for teams right now to be aggressive and these terms look to be a concession to the current mood.

Lastly, the Sponsors have built in a sizeable forward purchase of $150 million, which sets up the team nicely for negotiations with targets.  At a minimum, they will have $150 million in cash to work with.

We’ll watch for any changes as subsequent amendments get filed.  Stay tuned.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved